| 20.12 Real-Time Quote |  -0.27 / -1.32%Today’s Change | 7.56 Today|||52-Week Range 23.03 | +92.72% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $2.3B |
Company Description
Isis Pharmaceuticals, Inc. engages in the development and commercialization of drugs to treat various health conditions, including inflammatory, viral, metabolic and cardiovascular and dermatological diseases and cancer. The company operates in two segments: Drug Discovery & Development and Regulus. The Drug Discovery & Development segment exploits a novel drug discovery platform created to generate a broad pipeline of first-in-class drugs for the company and for its partners. The Regulus segment focuses on developing microRNA-targeted therapeutics in cancer, fibrosis, metabolic disorders and inflammatory disorders. Isis Pharmaceuticals was founded by Stanley T. Crooke in January 1989 and is headquartered in Carlsbad, CA.
Employees
Shareholders
| Individual stakeholders | 8.03% |
| Mutual fund holders | 51.14% |
| Other institutional | 34.03% |
Top Executives
| Stanley T. Crooke, MD, PhD | Chairman, President & Chief Executive Officer |
| B. Lynne Parshall, | Chief Operating Officer, Secretary & Director |
| Elizabeth L. Hougen, MBA | Chief Financial Officer & Senior Vice President |
| C. Frank Bennett, PhD | Senior Vice President-Research |
| Patrick R. ONeill | Senior Vice President, Legal and General Counsel |
.
